Brief: AIM Vaccine Posts H1 Gross Profit RMB 388.3 Million
29/08/2024 13:17
Aug 29 (Reuters) - AIM Vaccine H1 revenue RMB 537.2 million. * H1 gross profit RMB 388.3 million * H1 gross margin 72.3% * H1 capex RMB 119.5 million
Recent news on AIM Vaccine
See all newsBrief: AIM Vaccine Co Submits Application For Human Diploid Cell Rabies Vaccine In China
Brief: AIM Vaccine Says Tibet Bohai To Subscribe 37.4 Million Shares At RMB1.07 Each
Brief: AIM Vaccine Approves Issuance Of Up To 40 Million Domestic Shares
Brief: Aim Vaccine Says Serum-Free Rabies Vaccine Passes Inspection
Brief: AIM Vaccine Updates On 20-Valent Pneumococcal Polysaccharide Conjugate Vaccine